摘要
核药物/放射性药物是实现核医学分子成像和临床精准诊疗的关键。放射性金属核素因其优良的理化性质,成为核药物开发不可或缺的内容,拓展了正电子发射体层成像(PET)等成像技术的临床应用空间。就目前常用的放射性金属核素的理化性质、与金属核素适配的螯合剂、相对应的分子探针/核药物及其生物医学应用等进行综述与展望。
Nuclear drug/radiopharmaceutical is the key to achieving precise clinical diagnosis and treatment of nuclear medicine molecular imaging.Due to their excellent physicochemical properties,radiometallic nuclides have become an indispensable part of radiopharmaceutical development,expanding the clinical application space of PET and other radiography technologies.In this paper,the physicochemical properties of commonly used radiometallic nuclides,chelating agents suitable for metal nuclides,corresponding molecular probes/radiopharmaceuticals and their biomedical applications are reviewed and prospected.
作者
张志豪
朱晨亿
丛容
张涛
ZHANG Zhihao;ZHU Chenyi;CONG Rong;ZHANG Tao(Department of Radiopharmaceuticals,and Nuclear Medicine Clinical Translation Center,School of Pharmacy,Nanjing Medical University,Nanjing 211166,China)
出处
《国际医学放射学杂志》
北大核心
2023年第3期333-339,347,共8页
International Journal of Medical Radiology
基金
国家自然科学基金(12275135)
江苏省高等学校自然科学研究面上项目(21KJB350015)。
关键词
放射性金属核素
分子探针
正电子发射体层成像
单光子发射体层成像
诊疗一体化
核医学
Radiometallic nuclides
Molecular probe
Positron emission tomography
Single-photon emission computed tomography
Integration of diagnosis and treatment
Nuclear medicine
